US Court Denies Teva, Sun Motion To Reverse Generic Protonix Patent Litigation
Wyeth and Nycomed’s request for FDA to reset the date of Teva’s final approval to January 2011, based on the fact that Teva has patent defenses remaining at
Faeth Therapeutics has received the US Food and Drug Administration’s (FDA) fast track designation for the sapanisertib and serabelisib (PIKTOR) with paclitaxel combination to treat advanced or recurrent endometrial cancer.